Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Orbis Medicines has raised $93.2M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Orbis Medicines's investors include New Enterprise Associates, Eli Lilly, Cormorant Asset Management, Novo Holdings, Forbion Capital Partners.
Orbis Medicines is headquartered in Frederiksberg, Denmark.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Orbis Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orbis Medicines — Funding & Investors." VCBacked, January 6, 2025, https://www.vcbacked.co/company/orbis-medicines. Accessed July 19, 2026.
VCBacked. (2025). Orbis Medicines — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/orbis-medicines
{{cite web |title=Orbis Medicines — Funding & Investors |url=https://www.vcbacked.co/company/orbis-medicines |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated